Abstract
This publication provides information about recent study revealing relationship between low PU.1 expression in MDS-high risk progenitors and overall survival of MDS-high risk patients on AZA treatment. It also mentions development of detection kit for measuring chromatin changes on PU.1 gene regulatory regions.
These chromatin events can be used as prognostic markers for efficiency of AZA treatment in MDS-high risk patients.